‘s study in rectal cancer found that mice treated with RT+IL-2 had a higher percentage of CD4+T cells but a lower percentage of Tregs and MDSC in splenocytes, Administering IL-2 significantly improved the anti-tumour impact of RT (100). Here, IL2 is linked to rectal cancer.